Core Viewpoint - Triple-negative breast cancer (TNBC) is characterized by high invasiveness and poor prognosis due to the lack of specific treatment targets and high rates of postoperative recurrence and metastasis. Current treatments primarily involve surgical resection followed by chemotherapy, but inherent chemotherapy resistance necessitates new effective treatment strategies. The study introduces a promising approach using nanozyme-based therapy for postoperative adjuvant treatment of TNBC [1][4][7]. Group 1: Research Background - TNBC is the most aggressive subtype of breast cancer, with high recurrence and mortality rates. It lacks expression of estrogen receptors, progesterone receptors, and HER2, leading to a lack of precise treatment targets. The main treatment methods are surgical resection and postoperative chemotherapy, but challenges such as residual metastatic lesions and chemotherapy resistance contribute to high recurrence and metastasis rates [4][5]. - Recent studies indicate that immune checkpoint blockade (ICB) therapy shows potential in TNBC treatment due to the high density of tumor-infiltrating lymphocytes. However, resistance to immune checkpoint inhibitors and low immune response limit treatment efficacy, highlighting the need for enhanced antitumor immunity [4][5]. Group 2: Study Findings - The research combines iron-based unit point nanozymes (MFCA) with a responsive hydrogel delivery system to address two key challenges in TNBC treatment: eliminating residual tumor satellite lesions and inhibiting postoperative metastasis. This hydrogel composite can be directly injected into the surgical cavity for sustained release of MFCA, inducing ferroptosis in TNBC cells and enhancing immunogenicity [2][6]. - The study developed a biodegradable unit point nanozyme-loaded hydrogel that effectively inhibits postoperative metastasis and systemic recurrence in TNBC, providing a direct, efficient, and safe adjuvant treatment method to improve patient prognosis [7].